Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26518372 | 0.86 | FCER2 (0.33) | TDP1 | |
| SCHEMBL12989556 | 0.83 | CYP2D6 (0.46) | ALDH1A1CYP1A2 | |
| SCHEMBL16790758 | 0.80 | APEX1 (0.39) | CES2ALDH1A1TDP1CYP1A2 | |
| SCHEMBL24915512 | 0.80 | ACE (0.34) | CES2 | |
| SCHEMBL12134777 | 0.77 | — | — | |
| SCHEMBL12934316 | 0.77 | — | — | |
| SCHEMBL24915216 | 0.76 | MME (0.34) | CES2ALDH1A1TDP1 | |
| SCHEMBL8424785 | 0.76 | CA1 (0.34) | TDP1 | |
| SCHEMBL12055917 | 0.75 | CYP1A2 (0.46) | ALDH1A1CYP1A2TSHR | |
| SCHEMBL19992341 | 0.75 | CES2 (0.32) | CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374073-A1 | DIMERIC MILLA IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CES2 4883/4885ALDH1A1 3750/4885TDP1 3257/4885 |
| US-20230374073-A1 | DIMERIC MILLA IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CES2 4875/4885ALDH1A1 3255/4885TDP1 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.